Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Prasanthi Kandula

Procedural Dermatology Saint Louis, MO Medical Doctor

NPI 1225458185 CMS profile 1251952

10287 Clayton Rd Ste 360, Saint Louis, MO 63124

Open in the dashboard

General payments

$5,539

205 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Prasanthi Kandula of Saint Louis, MO is reported in the CMS Open Payments database as having received $5,539 across 205 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 69th percentile of Procedural Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $998 27
2024 General $494 16
2023 General $934 31
2022 General $571 18
2021 General $827 45
2020 General $533 28
2019 General $1,182 40

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Prasanthi Kandula
  • Procedural Dermatology median
  • Middle half of Procedural Dermatology
  • National median

In program year 2025, general payments to Prasanthi Kandula were reported at $998. Among 381 Procedural Dermatology profiles paid that year, the median was $592 and the middle half received between $144 and $1,778.

Show as a table
Year Prasanthi Kandula Procedural Dermatology median Middle half National median
2019 $1,182 $454 $152–$1,260 $163
2020 $533 $243 $90–$835 $114
2021 $827 $337 $102–$1,128 $132
2022 $571 $443 $119–$1,654 $149
2023 $934 $583 $137–$1,838 $160
2024 $494 $611 $132–$1,835 $164
2025 $998 $592 $144–$1,778 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $935 41 payments
  2. Janssen Biotech, Inc. $524 22 payments
  3. Galderma Laboratories, L.P. $516 24 payments
  4. Lilly USA, LLC $330 12 payments
  5. Pfizer Inc. $273 10 payments
  6. Genzyme Corporation $233 7 payments
  7. Biofrontera Inc. $215 2 payments
  8. Sun Pharmaceutical Industries Inc. $198 7 payments
  9. LEO Pharma Inc. $180 8 payments
  10. VYNE Pharmaceuticals Inc. $162 10 payments
  11. Other $1,975 62 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,444 204 payments
  2. Education $95 1 payment
Products named General payments · program years 2019–2025
  1. SKYRIZI $567 26 payments
  2. DUPIXENT $451 10 payments
  3. HUMIRA $333 12 payments
  4. TREMFYA $310 14 payments
  5. SIMPONI ARIA $268 10 payments
  6. STELARA $268 10 payments
  7. SIMPONI $268 10 payments
  8. CIBINQO $254 9 payments
  9. EUCRISA $244 9 payments
  10. OLUMIANT $229 7 payments
  11. Other $4,013 144 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

25

Median for Dermatology: 534

Drug cost

$398

Median for Dermatology: $67,151

Branded share of claims

0%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ketoconazole Generic 25 $398

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 38 billing codes

Paid by Medicare

$28,756

Medicare's payments for the services billed

Medicare patients

121

Average age 76

Services billed

482

63 women, 58 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 61%
Arthritis 33%
Osteoporosis 26%
Cancer 20%
Ischemic heart disease 18%
Atrial fibrillation 18%
Diabetes 16%
Chronic kidney disease 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DAXXIFY
  • REVANCE THERAPEUTICS, INC. $95
$95 — —
SKYRIZI
  • AbbVie, Inc. $58
$58 — —
TREMFYA
  • Janssen Biotech, Inc. $55
$55 — —
RINVOQ
  • AbbVie, Inc. $34
$34 — —
Bimzelx
  • UCB, Inc. $24
$24 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

205 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record